Fig. 7

TSPAN18 overexpression correlates with bone metastasis and poor prognosis in PCa. a Representative immunohistochemical staining images of TSPAN18 in benign prostatic hyperplasia (BPH) and PCa with Gleason (3+3) or Gleason (4+4). Scale bars: red, 50 μm. b The expression difference of TSPAN18 between BPH and PCa tissues. c-d The expression difference of TSPAN18 between low Gleason score ((6-7(3+4)) PCa tissues and high Gleason score (7(4+3)-10) PCa tissues in Cohort 1 (c) and Cohort 2 (d). e-f The expression difference of TSPAN18 between PCa tissues with or without bone metastasis in Cohort 1 (e) and Cohort 2 (f). g-h Kaplan-Meier curves for overall survival of PCa patients with high or low expression of TSPAN18 in Cohort 1 (g) and Cohort 2 (h). i-j Kaplan-Meier curves for cancer-specific survial of PCa patients with high or low expression of TSPAN18 in Cohort 1 (i) and Cohort 2 (j). k Working model for regulation of STIM1 stability and bone metastasis of PCa by TSPAN18. The error bars mean standard deviations of three independent experiments. *p<0.05, student’s t test